Risk-based pricing models and the role they might play in patients' access to new stem cell therapies.

IF 2.4 4区医学 Q4 CELL & TISSUE ENGINEERING

Regenerative medicine Pub Date : 2024-12-18 DOI:10.1080/17460751.2024.2441642

Klaus Hoeyer, Anne Sofie Borsch, Kim Bak Jensen, Agnete Kirkeby, Casper Steenholdt, Sarah Wadmann

引用次数: 0

Abstract

Stem cell research is currently undergoing a promising transformation from primarily basic research to increasing emphasis on translation and clinical trials. To reach patients, however, stem cell treatments need to be not only technically but also economically viable. In this commentry we present insights into emerging pricing models that may help ensure access to advanced and expensive treatments like stem cell therapies. Further, we present some reflections on the practical and ethical challenges that these models involve. We provide this information to allow the field of translational stem cell research to think ahead and to raise awareness of the outstanding social and ethical issues.

查看原文本刊更多论文

干细胞研究目前正经历着一个充满希望的转变，从以基础研究为主转向日益重视转化和临床试验。然而，要让患者接受干细胞治疗，不仅需要技术上可行，还需要经济上可行。在这篇评论中，我们深入探讨了新出现的定价模式，这些模式可能有助于确保人们获得干细胞疗法等先进而昂贵的治疗方法。此外，我们还对这些模式所涉及的实际和伦理挑战进行了一些思考。我们提供这些信息，是为了让干细胞转化研究领域进行前瞻性思考，并提高对悬而未决的社会和伦理问题的认识。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Regenerative medicine 医学-工程：生物医学

CiteScore

4.20

自引率

3.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization. Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.